Enhance your patent search with AI. Try the FREE AI-powered tool

A Tale of Two Vaccines: A Closer Look at Pfizer and Moderna

medtech putting samples on dish

On November 16, Moderna claimed the latest breakthrough with its vaccine candidate mRNA-1237, deemed 94.5% effective against COVID-19 — just within striking distance of Pfizer’s vaccine, which demonstrated 95% efficacy according to the pharma giant.

CureVac, Pfizer, Gilead, et al: Who will lead the COVID-19 vaccine race?

3d render of virus

As the COVID-19 pandemic spreads worldwide and the number of affected individuals continues to grow, the race is on to find a cure for the novel coronavirus. COVID-19 is a strain from the coronavirus family that causes illness from as mild as the common cold to more severe cases such as pneumonia, severe acute respiratory syndrome, kidney failure, and to the most extreme case, death.

Subscribe to our newsletter

  • Questions? Check our privacy policy.
  • This field is for validation purposes and should be left unchanged.

Patent and IP updates straight to your inbox

Sign up now to receive monthly patent news, analysis and free insight reports.

We don’t spam, we promise.